These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 27699930)

  • 21. Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients.
    Dalla Costa G; Martinelli V; Moiola L; Sangalli F; Colombo B; Finardi A; Cinque P; Kolb EM; Haghikia A; Gold R; Furlan R; Comi G
    Ann Neurol; 2019 Apr; 85(4):606-610. PubMed ID: 30761586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease.
    Pereira JB; Westman E; Hansson O;
    Neurobiol Aging; 2017 Oct; 58():14-29. PubMed ID: 28692877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A validation study of manual atrophy measures in patients with Multiple Sclerosis.
    Cappelle S; Pareto D; Tintoré M; Vidal-Jordana A; Alyafeai R; Alberich M; Sastre-Garriga J; Auger C; Montalban X; Rovira À
    Neuroradiology; 2020 Aug; 62(8):955-964. PubMed ID: 32246177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Bridel C; Leurs CE; van Lierop ZYGJ; van Kempen ZLE; Dekker I; Twaalfhoven HAM; Moraal B; Barkhof F; Uitdehaag BMJ; Killestein J; Teunissen CE
    Neurology; 2021 Nov; 97(19):e1898-e1905. PubMed ID: 34504023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies.
    Axelsson M; Dubuisson N; Novakova L; Malmeström C; Giovannoni G; Lycke J; Gnanapavan S
    Acta Neurol Scand; 2019 May; 139(5):422-427. PubMed ID: 30657162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
    Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
    Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.
    Toorop AA; Noteboom S; Steenwijk MD; Gravendeel JW; Jasperse B; Barkhof F; Strijbis EM; Rispens T; Schoonheim MM; van Kempen ZL; Killestein J
    Mult Scler; 2024 Feb; 30(2):266-271. PubMed ID: 38235514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
    Novakova L; Axelsson M; Malmeström C; Zetterberg H; Björkhem I; Karrenbauer VD; Lycke J
    J Neurol Sci; 2015 Nov; 358(1-2):201-6. PubMed ID: 26342940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin D and axonal injury in multiple sclerosis.
    Sandberg L; Biström M; Salzer J; Vågberg M; Svenningsson A; Sundström P
    Mult Scler; 2016 Jul; 22(8):1027-31. PubMed ID: 26462862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of repeated intrathecal triamcinolone-acetonide application on cerebrospinal fluid biomarkers of axonal damage and glial activity in multiple sclerosis patients.
    Rommer PS; Kamin F; Petzold A; Tumani H; Abu-Mugheisib M; Koehler W; Hoffmann F; Winkelmann A; Benecke R; Zettl UK
    Mol Diagn Ther; 2014 Dec; 18(6):631-7. PubMed ID: 24986188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The association between retinal nerve fibre layer thickness and N-acetyl aspartate levels in multiple sclerosis brain normal-appearing white matter: a longitudinal study using magnetic resonance spectroscopy and optical coherence tomography.
    Pardini M; Botzkowski D; Müller S; Vehoff J; Kuhle J; Ruberte E; Würfel J; Gass A; Valmaggia C; Tettenborn B; Putzki N; Yaldizli Ö
    Eur J Neurol; 2016 Dec; 23(12):1769-1774. PubMed ID: 27591406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.
    Romme Christensen J; Ratzer R; Börnsen L; Lyksborg M; Garde E; Dyrby TB; Siebner HR; Sorensen PS; Sellebjerg F
    Neurology; 2014 Apr; 82(17):1499-507. PubMed ID: 24682973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
    Wessels MH; Van Lierop ZY; Noteboom S; Strijbis EM; Heijst JA; Van Kempen ZL; Moraal B; Barkhof F; Uitdehaag BM; Schoonheim MM; Killestein J; Teunissen CE
    Mult Scler; 2023 Sep; 29(10):1229-1239. PubMed ID: 37530045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of neurofilament light chain in natalizumab therapy for different phases of multiple sclerosis: A systematic review and meta-analysis.
    Liu N; Sun M; Zhang W; Sun J; Gong P; Wang H; Wang M
    J Clin Neurosci; 2022 Jul; 101():198-203. PubMed ID: 35617924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurofilament light chain and MRI volume parameters as markers of neurodegeneration in multiple sclerosis.
    Filippi P; Vestenická V; Siarnik P; Sivakova M; Čopíková-Cudráková D; Belan V; Hanes J; Novák M; Kollar B; Turcani P
    Neuro Endocrinol Lett; 2020 Apr; 41(1):17-26. PubMed ID: 32338853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.
    Mañé-Martínez MA; Olsson B; Bau L; Matas E; Cobo-Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
    J Neuroimmunol; 2016 Oct; 299():112-117. PubMed ID: 27725108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in brain atrophy indices in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
    Arpín EC; Sobrino TG; Vivero CD; del Campo Amigo Jorrín M; Regal AR; González JP; Bouzas ML
    Neurodegener Dis Manag; 2016; 6(1):5-12. PubMed ID: 26782312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical impact of early brain atrophy in clinically isolated syndromes.
    Pérez-Miralles F; Sastre-Garriga J; Tintoré M; Arrambide G; Nos C; Perkal H; Río J; Edo MC; Horga A; Castilló J; Auger C; Huerga E; Rovira A; Montalban X
    Mult Scler; 2013 Dec; 19(14):1878-86. PubMed ID: 23652215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis.
    Adams A; Tilden W; Bestwick J; Holden D; Bianchi L; Smets I; Giovannoni G; Gnanapavan S
    Eur J Neurol; 2022 Sep; 29(9):2754-2760. PubMed ID: 35615966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.